Sam’s Club gears up for free digestive health screening
BENTONVILLE, Ark. — Sam’s Club is offering a free digestive health screening this month.
Sam’s Club pharmacies will offer both members and nonmembers free screenings, while supplies last, on Nov. 12 between 11 a.m. and 3 p.m., which will include the EZ Detect stool blood test, a take-home colon test designed for early detection of such bowel disorders as colon cancer, ulcers, hemorrhoids, polyps, colitis, diverticulitis or fissures. The event also will include cholesterol, glucose, blood pressure and body mass index screenings. Glucose screenings are not available in Tennessee, Maryland or Hawaii, Sam’s Club noted.
"Every 10 minutes a life is lost to colon cancer. Although many people may consider colon screenings an embarrassing topic of conversation, this cancer can be detected early when treatment is most effective — or even prevented altogether," Sam’s Club health-and-wellness SVP Jill Turner-Mitchael said. "Our digestive health screenings are a simple way for members to take an active role in the prevention of digestive disorders, including the early discovery of colon cancer."
Health Market Science, PDX team up to provide access to provider database
KING OF PRUSSIA, Pa. — Health Market Science and PDX are offering PDX system clients access to the HMS Provider MasterFile, the companies said.
HMS, a company that supplies provider data and data management services, and PDX, which provides technology products for the retail pharmacy industry, said PDX Classic Pharmacy System and Enterprise Pharmacy System users would have the same access as "top-tier pharmacy chains across the country."
"Our mutual customers asked for a seamless way to access the HMS Provider MasterFile so they can confidently fill prescriptions and still maintain a consistent workflow," HMS COO Jeff Klein said. "HMS has the sources, the technology and the expertise to collect, aggregate and maintain a repository of 1.5 million prescribers and their associated credentials, demographics, practice status and DEA registration."
J&J submits new FDA application for Nucynta ER
TITUSVILLE, N.J. — A Johnson & Johnson subsidiary has sent a regulatory application to the Food and Drug Administration seeking approval for one of its drugs in treating diabetes-related pain.
J&J Pharmaceutical Research & Development announced Monday the submission of its supplemental new drug application for Nucynta ER (tapentadol) extended-release tablets. The company hopes the FDA will approve the drug for managing neuropathic pain related to diabetic peripheral neuropathy in adults. The FDA approved the drug for managing moderate to severe chronic pain in adults who require a continuous, around-the-clock opioid treatment.
Of the nearly 26 million Americans living with diabetes, about 60% to 70% of them have some form of neuropathy, of which diabetic peripheral neuropathy is the most common type, according to J&J. The condition causes pain or loss of feeling in the toes, feet, legs, hands and arms.